MetaCap

Sotera Health Company (SHC)

NASDAQ: SHCHealth CareMisc Health and Biotechnology ServicesUSD

15.91-0.30 (-1.85%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SHC stock chart

Technical analysis

Key statistics

All statistics
52-week range
13.09 – 19.85
Day range
15.81 – 16.31
Volume / Avg
1.73M / 2.20M
Beta
—

52-week range

$13.09$19.85

SHC stock today

Sotera Health (SHC) closed at $15.91 on Nov 20, down 1.85% (-$0.30), versus the S&P 500's 3.70% decline. At this level, SHC sits in the middle of its 52-week range of $13.09 to $19.85: 19.8% below the high, set on Jan 9, 2026 and 21.5% above the low. SHC is down 9.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 2.6%.

At 26.5x trailing earnings, Sotera Health trades above the peer-group median of 22.4x. Its forward P/E of 14.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Sotera Health

Company profile

Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets.

Industry
Misc Health and Biotechnology Services
CEO
Mr. Alton E. Shader
Headquarters
Broadview Heights, OH
Employees
3,000
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Sotera Health generated $1.16 billion in revenue, up 5.7% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $77.9 million (+75.6% year over year), for a net margin of 6.7% versus a median of 4.0% in the prior 5 years. Gross margin was 55.5% (up from 54.7%).

Sotera Health annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.16B$1.10B$1.05B$1.00B$931.48M
Growth+5.74%+4.88%+4.54%+7.75%+13.85%
Net income$77.95M$44.40M$51.38M$-233.57M$116.88M
EPS (diluted)$0.27$0.16$0.18$-0.83$0.41

Analyst forecast

Forecast

Consensus (10 analysts)

buy

Avg. price target

$21.44+34.76%

  • Strong buy 3
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 1

Target range

Low $15.00High $25.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$0.20 vs $0.24
Surprise
-16.67%

SHC news

All SHC news

Sotera Health peers

Health Care sector
SHC peer companies
CompanyPrice% ChgMarket capCompare
PGNYProgyny Inc.35.71+0.73%$2.63Bvs SHC
AGLagilon health inc.90.24+0.83%$1.52Bvs SHC
VMDViemed Healthcare Inc.8.52-1.05%$322.85Mvs SHC
PARKPark Dental Partners Inc.17.03-6.79%$94.26Mvs SHC
CCELCryo-Cell International Inc.4.150.00%$33.46Mvs SHC
MGRXMangoceuticals Inc.0.1236-7.55%$2.75Mvs SHC
NIVFNewGenIvf Group Limited Class A0.0269-23.14%$80.77Kvs SHC
DVADaVita Inc.161.03+3.00%$10.13Bvs SHC

Indexes, lists and sector

Sotera Health stock FAQ

What is Sotera Health's stock price today?

SHC last traded at $15.91 as of Nov 20, 4:00 PM EST, down 1.85% on the day. Prices are delayed at least 15 minutes.

What is SHC's P/E ratio?

SHC trades at a trailing P/E ratio of 26.52 and a forward P/E of 14.94, compared with a median of 22.4 for its closest peers.

Who is Sotera Health's CEO?

Mr. Alton E. Shader is the chief executive officer of Sotera Health Company, which has about 3,000 employees.

What is the SHC 52-week high?

The 52-week high for SHC is $19.85 and the 52-week low is $13.09. The stock is currently 19.8% below its high.

Compare SHC